Insights
![](https://bereskinparr.com/wp-content/uploads/2023/05/InsightsNews_Insights_Header_1100x515.jpg)
Updating results
Showing results 1 - 24 of 40 Results per page:
No results found.
Explore our Insights
![](https://bereskinparr.com/wp-content/uploads/2023/04/BP_Insights_Events_Thumb08_660x880-365x487.jpg)
![](https://bereskinparr.com/wp-content/uploads/2023/04/BP_Insights_Events_Thumb10_660x880-365x487.jpg)
![](https://bereskinparr.com/wp-content/uploads/2023/04/BP_Insights_Events_Thumb08_660x880-365x487.jpg)
![](https://bereskinparr.com/wp-content/uploads/2023/04/BP_Insights_Events_Thumb05_660x880-365x487.jpg)
![](https://bereskinparr.com/wp-content/uploads/2023/04/BP_Insights_Events_Thumb03_660x880-365x487.jpg)
![](https://bereskinparr.com/wp-content/uploads/2023/04/BP_Insights_Events_Thumb01_660x880-365x487.jpg)
June 6, 2023
Federal Court of Appeal Clarifies Test for Inducing Infringement for Generic/Biosimilar Drugs
›![](https://bereskinparr.com/wp-content/uploads/2023/09/BP_News_Events_EXTRAS_660x880_62250094-365x487.jpg)
![](https://bereskinparr.com/wp-content/uploads/2023/09/BP_News_Events_EXTRAS_660x880_18136510-365x487.jpg)
January 16, 2023
Chirality Matters: Dismissal of Janssen’s Judicial Review Confirms Enantiomers Are Not “Innovative Drugs” for Obtaining Data Protection
›![](https://bereskinparr.com/wp-content/uploads/2023/09/BP_News_Events_EXTRAS_660x880_63740479-365x487.jpg)
December 23, 2022
Patented Medicines Regulations: The Problem Is Not in Collecting the Data, but in How You Use It!
›![](https://bereskinparr.com/wp-content/uploads/2023/09/BP_News_Events_EXTRAS_660x880_324734822-365x487.jpg)
November 16, 2022
USSC Agrees to Reconsider Amgen Inc. v Sanofi on Enablement of Antibody Genus Claims
›![](https://bereskinparr.com/wp-content/uploads/2023/09/BP_News_Events_EXTRAS_660x880_378224113-365x487.jpg)
![](https://bereskinparr.com/wp-content/uploads/2023/09/BP_News_Events_EXTRAS_660x880_739496338-365x487.jpg)
Subscribe to our newsletter
![](https://bereskinparr.com/wp-content/uploads/2023/09/BP_News_Events_EXTRAS_660x880_2231570535-365x487.jpg)
![](https://bereskinparr.com/wp-content/uploads/2023/04/BP_Insights_Events_Thumb01_660x880-365x487.jpg)
![](https://bereskinparr.com/wp-content/uploads/2023/09/BP_News_Events_EXTRAS_660x880_51674026-365x487.jpg)
June 2, 2022
Federal Court sets aside Minister of Health’s approval of RUZURGI for the second time over data protection dispute
›![](https://bereskinparr.com/wp-content/uploads/2023/09/BP_News_Events_EXTRAS_660x880_191836994-365x487.jpg)
![](https://bereskinparr.com/wp-content/uploads/2023/09/BP_News_Events_EXTRAS_660x880_1937388811-365x487.jpg)
![](https://bereskinparr.com/wp-content/uploads/2023/09/BP_News_Events_EXTRAS_660x880_51674026-365x487.jpg)
![](https://bereskinparr.com/wp-content/uploads/2023/09/BP_News_Events_EXTRAS_660x880_142397470-365x487.jpg)
![](https://bereskinparr.com/wp-content/uploads/2023/09/BP_News_Events_EXTRAS_660x880_1299757657-365x487.jpg)
November 19, 2021
Federal Court finds Minister of Health’s refusal of BELSOMRA CSP unreasonable, remits for redetermination
›![](https://bereskinparr.com/wp-content/uploads/2023/09/BP_News_Events_EXTRAS_660x880_62250094-365x487.jpg)
![](https://bereskinparr.com/wp-content/uploads/2023/09/BP_News_Events_EXTRAS_660x880_219242479-365x487.jpg)
![](https://bereskinparr.com/wp-content/uploads/2023/09/BP_News_Events_EXTRAS_660x880_2080466386-365x487.jpg)
July 9, 2021
Inducing Infringement by Product Monographs & Skill and Judgment in Medical Use Claims: Key Takeaways from the Federal Court’s decision in Hoffman-La Roche Limited v Sandoz Canada Inc.
›![](https://bereskinparr.com/wp-content/uploads/2023/04/BP_Insights_Events_Thumb02_660x880-365x487.jpg)
Loading...
Showing results 1 - 24 of 40 Results per page:
No results found.